

Amikacin

Amikacin dosing is weight based; ensure accuracy of documented weight before administration		
Reserve Antimicrobial Refer to CUH Antimicrobial Guidelines on Eolas for further information		
CAUTION: High Administration Risk Rating		
Form	500mg per 2mL vial	Store below 25°C
Reconstitution	Already in solution	
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%	
Administration	IV Infusion	
	Dilute in 100mL of compatible fluid. Infuse over 30mins.	
Extravasation	<u>IM Injection (avoid if possible)</u>	
	Give by deep IM injection.	
Monitoring	Amikacin has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely using a recognised phlebitis scoring tool. Re-site cannula at first signs of inflammation.	
Additional Information	Monitor renal function and plasma drug levels. Take first sample (trough level) immediately prior to scheduled second dose. Refer to CUH Antimicrobial guidelines on Eolas for further guidance. Vestibular and auditory function if treatment is likely to be longer than 7 to 10 days. • Patients should be well hydrated. • To avoid excessive dosage in obese patients (where Actual Body Weight is more than 120% of Ideal Body Weight), use Adjusted Bodyweight to calculate dose – see the CUH Antimicrobial Guidelines on Eolas for guidance.	

Information provided relates to Amikacin (Caragen) and Normon (unlicensed).